⌕
Kardigan · KARD · Nasdaq
Tenet — · insufficient data
Compare
$13.17−4.71%Market open
$13.17−0.65 (−4.71%)
Market open · 15-min delayed · as of 11:30 AM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Kardigan (KARD) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is KARD's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 12, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan today reported financial results for the third quarter ended September 30, 2026, and provided recent business updates.…

KARD −4.7% todayRead at source ↗
● Business WireNov 11, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Kardigan to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan today announced that the company will participate in a fireside chat at the 2026 Jefferies London Healthcare Conference on Nove…

KARD −4.7% todayRead at source ↗
● Seeking AlphaNov 7, 2026 · 12:44 ET
Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript

Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript…

KARD −4.7% todayRead at source ↗
● MarketBeatNov 7, 2026 · 11:16 ET
Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results

Kardigan NASDAQ: KARD said its phase 2 trial of investigational drug ataciguat in aortic stenosis is fully enrolled and that it will assess the study's primary endpoint at 48 weeks, rather than 24 weeks. Top-line results…

KARD −4.7% todayRead at source ↗
● Business WireNov 6, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS).…

KARD −4.7% todayRead at source ↗
● Business WireSep 30, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committ…

KARD −4.7% todayRead at source ↗
● Defense WorldSep 30, 2026 · 06:44 ET
Kardigan, Inc. (NASDAQ:KARD) Stock Has Consensus Price Target of $42.25 According to Analysts

Shares of Kardigan, Inc. (NASDAQ: KARD - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst h…

KARD −4.7% todayRead at source ↗
● Seeking AlphaSep 13, 2026 · 06:10 ET
Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

Kardigan targets genetic DCM, moderate CAVS, and post-hospitalization ASH with differentiated, biology-driven clinical programs. KARD holds $660.7M in liquid assets, providing roughly 2–3 years of runway to achieve key c…

KARD −4.7% todayRead at source ↗
● Business WireSep 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Kardigan to Present at Two September Investor Conferences

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan will participate in two upcoming investor conferences: 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthc…

KARD −4.7% todayRead at source ↗

No upcoming events in the feeds.

NVDA9−2.3%
ABR2−5.6%
ARMK2−1.0%
BBWI2−7.3%

Article counts from the last market-wide feed page, across every symbol we track and not just KARD · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.